세계의 미세잔존질환 검사 시장 예측(-2029년) : 제품별, 기술별, 용도별, 최종사용자별, 지역별

Minimal Residual Disease Market by Product (Kits, Instruments), Technology (PCR, NGS), Application (Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors), End User (Hospitals, Diagnostic Labs, Research Institutes), & Region - Global Forecast to 2029

US $ 4,950 ￦ 7,089,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,524,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,672,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,322,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

미세잔존질환(MRD) 검사 시장 규모는 2024년 추정 14억 3,000만 달러에서 2029년에는 25억 5,000만 달러에 달할 것으로 보이며, 예측 기간 중 CAGR은 12.2%로 예측됩니다.

전 세계에서 암 퇴치 프로그램에 대한 자금 지원 및 보조금 증가가 MRD 검사 시장의 중요한 성장 요인으로 부상하고 있습니다. 현재 세계보건기구(WHO)와 세계기금을 포함한 각국 정부 및 국제기구는 암 발병률 증가에 대응하기 위해 막대한 자금을 투입하고 있으며, 특히 조기발견 및 예방에 많은 노력을 기울이고 있습니다. 이러한 자금은 특히 의료 인프라가 취약한 고부담 지역에서 진단 시설에 대한 접근성을 개선하기 위해 투입되고 있습니다. 또한 암의 정확한 진단과 적절한 관리를 위해 환자를 담당하는 의료 전문가들의 교육도 장려하고 있습니다. 이와는 별도로, 연구 보조금과 국제 협력은 암 검사가 일상적인 의료 서비스에 통합될 수 있도록 지원하고 있습니다. 이러한 자금 지원 증가로 MRD 검사가 가능해지면서 전 세계 암 퇴치 노력이 강화되고 있습니다. 이는 전 세계 미세잔존병변 검사 시장의 성장을 가속하고 있습니다.

조사 범위
조사 대상년	2022-2029
기준년	2023년
예측 기간	2024-2029
검토 단위	금액(달러)
부문	제품별, 기술별, 용도별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가

MRD 검사 시장은 제품별로 분석 키트 및 시약과 기기로 구분됩니다. 분석 키트 및 시약은 예측 기간 중 가장 높은 CAGR을 차지할 것으로 예상됩니다. 주요 촉진요인 중 하나는 검사의 높은 정확도입니다. 고위험군에 대한 이러한 검사의 보급이 수요 증가를 지원하고 있으며, WHO를 포함한 다양한 국제 보건기구의 규제 승인 및 권장 사항도 채택 확대에 기여하고 있습니다. 이러한 요인에 더해 암 연구에 대한 자금 지원 증가와 진단 방법의 발전은 MRD 검사 키트 시장의 높은 성장세를 견인하고 있습니다.

미세잔존병변 검사 시장은 용도별로 혈액 악성 종양, 고형 종양 및 기타 용도로 분류되며, 2021년에는 혈액 악성 종양 부문이 가장 큰 점유율을 차지했습니다. 이 부문의 성장에 기여하는 요인은 백혈병, 림프종 및 그 유형의 발생률 증가와 이러한 질병에 대한 환자의 지속적인 모니터링에 대한 인식입니다.

세계 MRD 검사 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분류됩니다. 특히 아시아태평양이 예측 기간 중 가장 큰 성장을 이룰 것으로 예상됩니다. 아시아태평양은 인도, 중국 등 결핵 발병률이 높아 암 검진 및 관리가 필수적인 지역입니다. 정부 및 국제기구의 재정 지원과 암 퇴치 캠페인의 확대는 아시아태평양의 진단 및 의료 인프라에 대한 접근성을 향상시키는 데 기여하고 있습니다. 지역사회와 의료진 사이에서 암 조기 발견의 필요성에 대한 인식이 높아지면서 검사에 대한 수요가 크게 증가하고 있으며, MRD 검사 시장의 또 다른 주요 성장 요인으로 의료비 증가와 규제 프레임워크의 변화로 인한 의료비 지출 증가가 있습니다. 이러한 모든 요인들이 아시아태평양의 MRD 검사 시장의 성장을 가속하고 있습니다.

세계의 미세잔존질환 검사 시장에 대해 조사했으며, 제품별, 기술별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 가격 분석
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 무역 분석
• 에코시스템 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 규제 분석
• 기술 분석
• 2023-2024년의 주요 컨퍼런스와 이벤트
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 투자와 자금조달 시나리오
• 사례 연구 분석
• AI/생성형 AI가 미세잔존질환 검사 시장에 미치는 영향

제6장 미세잔존질환 검사 시장(제품별)

• 서론
• 어세이 키트·시약
• 기기

제7장 미세잔존질환 검사 시장(기술별)

• 서론
• 중합효소 연쇄 반응
• 차세대 시퀀싱
• 유세포분석
• 기타

제8장 미세잔존질환 검사 시장(용도별)

• 서론
• 조혈 악성 종양
• 고형 종양
• 다발성골수종
• 기타

제9장 미세잔존질환 검사 시장(최종사용자별)

• 서론
• 병원과 전문 클리닉
• 진단 검사실
• 학술연구기관
• 기타

제10장 미세잔존질환 검사 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 기타
• 라틴아메리카
  • 시장을 활성화 시키기 위해 민간투자와 공공투자를 늘린다.
  • 라틴아메리카의 거시경제 전망
• 중동 및 아프리카
  • 시장을 촉진하기 위한 조사에 대한 자금 제공의 증가
  • 중동 및 아프리카의 거시경제 전망
• GCC 국가
  • 첨단 의료 인프라에 대한 주목과 조사 자금의 증대가 GCC 시장을 촉진
  • GCC 국가의 거시경제 전망

제11장 경쟁 구도

• 개요
• 주요 참여 기업의 전략/강점
• 매출 분석, 2019-2023년
• 시장 점유율 분석, 2023년
• 기업 평가 매트릭스 : 주요 참여 기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 기업 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제12장 기업 개요

• 주요 참여 기업
  • F. HOFFMANN-LA ROCHE AG
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • GUARDANT HEALTH, INC.
  • SYSMEX CORPORATION
  • NEOGENOMICS LABORATORIES
  • MOLECULARMD(A SUBSIDIARY OF ICON PLC)
  • ADAPTIVE BIOTECHNOLOGIES
  • ARCHERDX(INVITAE CORPORATION)
  • BIO-RAD LABORATORIES, INC.
  • NATERA, INC.
• 기타 기업
  • OPKO HEALTH, INC.
  • GENETRON HEALTH
  • QUEST DIAGNOSTICS, INC.
  • ASURAGEN, INC.
  • INVIVOSCRIBE, INC.
  • ARUP LABORATORIES INC.
  • MISSION BIO, INC.
  • CERGENTIS B.V.

제13장 부록

KSA

영문 목차

영문목차

The MRD testing market will rise in value from estimated USD 1.43 Billion in 2024 to USD 2.55 Billion in 2029, at a CAGR of 12.2% over the forecast period. Increased funding and grants for cancer control programs across the globe have emerged as an important growth factor in the MRD testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of cancer, especially in terms of early detection and prevention. These funds are being channelled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of cancer. Apart from that, research grants and international collaborations are also enabling cancer testing integration into routine health care services. Thus, this growing funding is rendering MRD tests available and enhancing the efforts to control cancer globally. This, in turn, is fuelling the growth of the global minimal residual disease testing market.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD)
Segments	Product, technology, application, end user, and region
Regions covered	North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries

"MRD Assay Kits & Reagents segment is expected to have the fastest growth rate in the MRD testing market, by product, during the forecast period."

The MRD testing market is segmented into assay kits & reagents, and instruments based on product. Assay kits & reagents are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy of tests. Growing penetration of these tests in high-risk populations, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in cancer and advancements in diagnostics are also driving the high growth of the test kits segment in the MRD testing market.

"Haematological malignancies segment accounted for the highest growth rate in the MRD testing market, by application, during the forecast period."

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

"Asia Pacific: The fastest-growing region in MRD testing market."

The worldwide market for MRD testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drives the need for essential cancer screening and management. Growth in government and international organization funding and campaigns against cancer has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of cancer has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the MRD testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the MRD testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the MRD testing market:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Managers - 30%, D-level - 50%, and Others - 20%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others - 4%

The key players in this market are are F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China).

Research Coverage:

This research report categorizes the MRD testing market by product (assay kits & reagents, instruments), by technology (PCR, NGS, flow cytometry, and other applications), by application (hematological malignancies, solid tumors, multiple myeloma, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the MRD testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the MRD testing market. Competitive analysis of upcoming startups in the MRD testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall MRD testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising incidence of cancer, and increased funding and grants for cancer control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the MRD testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the MRD testing market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the MRD testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the MRD testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ESTIMATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RESEARCH LIMITATIONS
• 2.9 RISK ASSESSMENT
  • 2.9.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
• 4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY PRODUCT, 2024 VS. 2029
• 4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029
• 4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2024 VS. 2029
• 4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.6 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of hematological malignancies
    • 5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
    • 5.2.1.3 Increasing cancer awareness initiatives by global health organizations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complex regulatory frameworks delaying approvals of new molecular diagnostics tests
    • 5.2.2.2 High cost of minimal residual disease testing kits
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging countries
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Unclear reimbursement scenario and policies for patients
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING TREND OF KEY PLAYERS, BY PRODUCT & REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA
  • 5.7.2 EXPORT DATA
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY LANDSCAPE
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East
    • 5.11.1.6 Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 PCR and NGS
  • 5.12.2 ADJACENT TECHNOLOGIES
    • 5.12.2.1 Digital PCR
• 5.13 KEY CONFERENCES & EVENTS IN 2023-2024
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
• 5.17 IMPACT OF AI/GEN AI ON MINIMAL RESIDUAL DISEASE TESTING MARKET

6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ASSAY KITS & REAGENTS
  • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO DRIVE MARKET GROWTH

7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 POLYMERASE CHAIN REACTION
  • 7.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
• 7.3 NEXT-GENERATION SEQUENCING
  • 7.3.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO SUPPORT ADOPTION
• 7.4 FLOW CYTOMETRY
  • 7.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
• 7.5 OTHER TECHNOLOGIES

8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 HEMATOLOGICAL MALIGNANCIES
  • 8.2.1 LEUKEMIA
    • 8.2.1.1 Myeloid leukemia
      • 8.2.1.1.1 High prevalence of AML in adults to support growth
    • 8.2.1.2 Lymphocytic leukemia
      • 8.2.1.2.1 High incidence of ALL in children to drive market
    • 8.2.1.3 Other leukemias
  • 8.2.2 LYMPHOMA
    • 8.2.2.1 Non-Hodgkin lymphoma
      • 8.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
    • 8.2.2.2 Hodgkin lymphoma
      • 8.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel demand for MRD testing
• 8.3 SOLID TUMORS
  • 8.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
• 8.4 MULTIPLE MYELOMA
  • 8.4.1 RISING INCIDENCE OF MULTIPLE MYELOMAS TO DRIVE MARKET
• 8.5 OTHER APPLICATIONS

9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & SPECIALTY CLINICS
  • 9.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
• 9.3 DIAGNOSTIC LABORATORIES
  • 9.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
• 9.5 OTHER END USERS

10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Increasing prevalence of cancer to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Availability of various cancer screening programs to support market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Government support for research funding to support MRD testing market
  • 10.3.3 UK
    • 10.3.3.1 Increasing number of diagnostic laboratories to propel market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising R&D expenditure in France to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Favorable funding scenario to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Consolidation of laboratories in Spain to support market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Growing public access to advanced healthcare facilities to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Universal healthcare reimbursement policy to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing private and public investments in healthcare system to drive market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
  • 10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 10.7 GCC COUNTRIES
  • 10.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE AND FUNDING IN RESEARCH TO DRIVE GCC MARKET
  • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 LIST OF EVALUATED VENDORS
  • 11.5.2 STARS
  • 11.5.3 EMERGING LEADERS
  • 11.5.4 PERVASIVE PLAYERS
  • 11.5.5 PARTICIPANTS
  • 11.5.6 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.6.1 Company footprint
    • 11.5.6.2 Product footprint
    • 11.5.6.3 Technology footprint
    • 11.5.6.4 Application footprint
    • 11.5.6.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 F. HOFFMANN-LA ROCHE AG
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 GUARDANT HEALTH, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches & approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 SYSMEX CORPORATION
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 NEOGENOMICS LABORATORIES
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 ADAPTIVE BIOTECHNOLOGIES
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 ARCHERDX (INVITAE CORPORATION)
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
      • 12.1.8.3.2 Deals
  • 12.1.9 BIO-RAD LABORATORIES, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 NATERA, INC.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 OPKO HEALTH, INC.
  • 12.2.2 GENETRON HEALTH
  • 12.2.3 QUEST DIAGNOSTICS, INC.
  • 12.2.4 ASURAGEN, INC.
  • 12.2.5 INVIVOSCRIBE, INC.
  • 12.2.6 ARUP LABORATORIES INC.
  • 12.2.7 MISSION BIO, INC.
  • 12.2.8 CERGENTIS B.V.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS

관련자료